ACM
PACB icon

AlphaCrest Capital Management’s Pacific Biosciences PACB Stock Holding History

AlphaCrest Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-31,382
Closed -$286K – 1335
2022
Q1 		$286K Buy
+31,382
New +$361K 0.02% 1119
2021
Q4 		– Sell
-9,700
Closed -$248K – 1422
2021
Q3 		$248K Buy
+9,700
New +$287K 0.01% 1162

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AlphaCrest Capital Management's PACB Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 31,382 shares — an estimated $286K sold.

AlphaCrest Capital Management first reported a position in PACB in Q3 2021 and held it in 2 quarters. The position peaked at $286K in Q1 2022. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

  • AlphaCrest Capital Management reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 31,382 Pacific Biosciences shares in Q2 2022, an estimated $286K.
  • AlphaCrest Capital Management first reported a position in Pacific Biosciences in Q3 2021 and held it in 2 quarters.
  • AlphaCrest Capital Management's Pacific Biosciences position peaked at $286K in Q1 2022.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.